NCT03061214: A reported trial by Novo Nordisk A/S
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03061214 |
|---|---|
| Title | Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 28, 2017 |
| Completion date | March 14, 2019 |
| Required reporting date | March 13, 2020, midnight |
| Actual reporting date | March 9, 2020 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |